Podcasts about Hepatology

ReferencesFront Immunol. 2017 Jun 9;8:643JAMA. 2021;325(16):1640-1649Journal of Hepatology 2012 56, 704-713DOI:(10.1016/j.Annual Review of Food Science and Technology.2022.  Volume 13:263-286Annual Review of Pathological Mechanisms of Disease 2010. 5:99-118.Nature.2013 Jul 4;499(7456):97-101 Nature Reviews Gastroenterology and Hepatology 26 April 2019Cell Metabolism 2019. [29] 4:886-900Lamm, R. 1972. "While the City Sleeps" Chicago Vhttps://music.youtube.com/watch?v=qCrgrGsBlr0&si=oGMvJDfCrd2BU7_ICetera and Seraphine . "Lowdown" Chicago IIIhttps://music.youtube.com/watch?v=6LlZCBbeZTk&si=DrSyAp9lCzhZyqfWLamm, R. 1969. "Questions 67 and 68" CTAhttps://music.youtube.com/watch?v=0TKaFqhmmg4&si=_W-MMatKBBQ0cBF9

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/44ySoL3Follow along with the slides: https://bit.ly/3IvwQrjGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/4lKaO2HFollow along with the slides: https://bit.ly/44PPBysGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

Host: Darryl S. Chutka, M.D. Guest: Edward V. Loftus JR, M.D. Inflammatory Bowel Disease is somewhat of an umbrella term for a group of chronic inflammatory conditions of the GI tract. The most common types include ulcerative colitis and Crohn's Disease. While there are similarities between the two, there are also differences. For many individuals with inflammatory bowel disease, it's only a mild illness. Unfortunately for some, it can lead to severe disability and potentially life-threatening complications. What are the similarities and differences between ulcerative colitis and Crohn's? When should we suspect a patient has an inflammatory bowel disease? What's the best way to establish a diagnosis and finally, what treatment options do we have? These are just some of the questions I'll be asking my guest, Edward V. Loftus JR, M.D., from the Division of Gastroenterology and Hepatology at the Mayo Clinic as we discuss “Inflammatory Bowel Disease and Its Treatment”. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

Host: Darryl S. Chutka, M.D. Guests: David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S. An early diagnosis of inflammatory bowel disease is important in preventing long-term complications. Prompt treatment can improve quality of life, reduce the likelihood of hospitalizations, and help maintain remissions. However, establishing a diagnosis is often challenging due to the nonspecific and fluctuating nature of symptoms. Inflammatory bowel disease can also mimic other GI conditions. In addition, diagnostic confirmation usually requires a combination of blood tests, imaging, endoscopy, and histological analysis, making the process both time consuming and complex.  The topic for today's podcast is “Diagnosing Inflammatory Bowel Disease and Monitoring Modalities” and my guests are David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S., from the Division of Gastroenterology and Hepatology at the Rochester campus of the Mayo Clinic. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease   Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts   

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes 2.    Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension Meta-Analysis 3.    The Diabetes Prevention Program and Its Outcomes Study: NIDDK's Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact 4.    Comparative effectiveness of alternative second‐line oral glucose‐lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data 5.    Phase 3 Trial of Semaglutide in Metabolic Dysfunction– Associated Steatohepatitis   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Welcome to the Choosing Wisely Campaign series! This is the third episode of a 6-part series exploring the ABIM Foundation's Choosing Wisely Lists. This campaign aims to promote conversations between clinicians and patients to avoid unnecessary medical tests, treatments, and procedures. Our second case-based episode presents an infant with diarrhea and diaper dermatitis. After a clear discussion of the case and thoughtful consideration of the etiology and treatment strategies, we use the AAP's Choosing Wisely dermatology and gastroenterology, hepatology, and nutrition lists to create a resource-conscious care plan that is safe and patient-centered. In the coming episodes, we'll explore the pediatric lists and apply our knowledge to cases of common presentations seen in primary and acute care pediatrics.    Series Learning Objectives: Introduction to the Choosing Wisely Campaign: Understand the origins, historical precedent, and primary goals of the campaign. Case-Based Applications: Explore five common presentations in primary and acute care pediatrics, applying concepts from various Choosing Wisely lists to guide management and resource stewardship. Effective Communication: Learn strategies for engaging in tough conversations with parents and colleagues to create allies and ensure evidence-based practices are followed. Modified rMETRIQ Score: 15/15   Competencies: AACN Essentials: 1: 1.1 g, 1.2f, 1.3de 2: 2.1 de, 2.2g, 2.4fg, 2.5 hijk 7: 7.2 ghk 9: 9.1ij, 9.2ij, 9.3ik NONPF NP Core Competencies: 1: NP1.1h, NP 1.2km, NP 1.3fjh 2: NP2.1jg, NP2.2kn, NP 2.4hi, NP2.5 klmno 7: NP7.2m 9: NP9.1mn, NP9.2n, NP9.3p   References ABIM Foundation. (2019). Communicating about overuse with vulnerable populations. Retrieved from https://www.choosingwisely.org/files/Communicating-About-Overuse-to-Vulnerable-Population_Final2.pdf AAP Section on Dermatology. (2021). Five things physicians and patients should question. https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWDermatology.pdf AAP Section on Gastroenterology, Hepatology, and Nutrition. (2023). Five things physicians and patients should question. https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWGastroenterology.pdf Harriet Lane Service (Johns Hopkins Hospital), Anderson, C. C., Kapoor, S., & Mark, T. E. (2024). The Harriet Lane handbook: a manual for pediatric house officers (23rd ed.). Elsevier.  Jauregui, J., Nelson, D., Choo, E., Stearns, B., Levine, A. C., Liebmann, O., & Shah, S. P. (2014). External validation and comparison of three pediatric clinical dehydration scales. PloS one, 9(5), e95739. https://doi.org/10.1371/journal.pone.0095739 Johnson, H., & Yu, J. (2022). Current and Emerging Therapies in Pediatric Atopic Dermatitis. Dermatology and therapy, 12(12), 2691–2703. https://doi.org/10.1007/s13555-022-00829-4 Semon, A. K., Keenan, O., & Zackular, J. P. (2021). Clostridioides difficile and the Microbiota Early in Life. Journal of the Pediatric Infectious Diseases Society, 10(Supplement_3), S3–S7. https://doi.org/10.1093/jpids/piab063

There's more than one way to screen for colon cancer—do you know your options? In this episode, three medical experts from the University of Maryland Midtown Health Center will walk you through the latest in screening options—from colonoscopies to FIT-DNA tests—and how to choose what's right for you. Learn the facts, understand your risks, and hear real stories of lives saved by timely screening.

Historically patients with alcohol-related liver disease have received poor quality of care during their admission. In 2014, a guidance bundle was released by the the British Society of Gastroenterology (BSG) and British Association for the Study of the Liver (BASL) to address this issue. This toolkit has recently received an update to incorporate recent advances in care and improve its usability as well as accessibility.  A panel of guests join the podcast to discuss the perils of "bundle fatigue", the importance of buy-in for implementing guidance, and QI strategies for bringing the updated bundle successfully to your practice. Dr Oliver Tavabie, Deputy Editor at FG and Hepatology Consultant at the Leeds Liver Unit along with Dr Kohilan Gananandan, Trainee Editor at FG and Hepatology Registrar Royal London Hospital, interview Professor Stuart McPherson and Drs Lynsey Corless and Giovanna McGinty. Professor Stuart McPherson is based at the Liver Unit at Newcastle Upon Tyne NHS Foundation Trust and is the deputy VP for Hepatology at the BSG. Dr Lynsey Corless is a Consultant Hepatologist at Hull Royal Infirmary and the NIHR Research Delivery Network National Specialty and Settings Lead for Hepatology. Dr Giovanna McGinty is a Specialist Gastroenterology Registrar at the North Bristol NHS Trust as well as an Associate Editor at FG. They are amongst the authors of the paper "Decompensated cirrhosis: an update of the BSG/BASL admission care bundle”, published online in Frontline Gastroenterology in April 2025.   We hope you enjoy the #FGPodcast. Please follow @‌FrontGastro_BMJ. Listen to our regular podcasts and subscribe in Apple Podcasts and Spotify. If you enjoy our podcast, please rate us on your chosen platform, and leave us a review on the Frontline Gastroenterology Podcast page on Apple Podcasts: https://podcasts.apple.com/gb/podcast/fg-podcast/id942944229

Un nouvel épisode du Pharmascope, à saveur pédiatrique, est disponible! Dans ce 158e épisode, Nicolas, Isabelle, Olivier et une illustre invitée discutent du RGO chez les tout-petits et les un peu plus vieux.  Les objectifs pour cet épisode sont les suivants: Expliquer les manifestations cliniques et la prise en charge du RGO en pédiatrie. Discuter de l'approche non-pharmacologique du RGO en pédiatrie. Comparer les données d'efficacité et d'innocuité des différents médicaments utilisés dans le traitement du RGO en pédiatrie. Ressources pertinentes en lien avec l'épisode  Rosen R, et coll. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):516-554. Chevalier I, Beck CE, Doré-Bergeron MJ, Orkin J; Société canadienne de pédiatrie. La prise en charge médicale du reflux gastro-œsophagien chez les nourrissons en santé. Nov 2022. Horvath A, Dziechciarz P, Szajewska H. The effect of thickened-feed interventions on gastroesophageal reflux in infants: systematic review and meta-analysis of randomized, controlled trials. Pediatrics. 2008 Dec;122(6):e1268-77. Kwok TC, Ojha S, Dorling J. Feed thickener for infants up to six months of age with gastro-oesophageal reflux. Cochrane Database Syst Rev. 2017 Dec 5;12(12):CD003211. Tighe MP, Andrews E, Liddicoat I, Afzal NA, Hayen A, Beattie RM. Pharmacological treatment of gastro-oesophageal reflux in children. Cochrane Database Syst Rev. 2023 Aug 22;8(8):CD008550. Fernández-González SM, Moreno-Álvarez A, Solar-Boga A. Proton Pump Inhibitors in Pediatric Gastroesophageal Reflux Disease: A Systematic Review of Randomized Controlled Trials. Children (Basel). 2024 Mar 1;11(3):296. Terrin G, et coll. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. 2012 Jan;129(1):e40-5. Canani RB, et coll; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006 May;117(5):e817-20. Lassalle M, Zureik M, Dray-Spira R. Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children. JAMA Pediatr. 2023 Oct 1;177(10):1028-1038. Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children. JAMA Pediatr. 2020 Jun 1;174(6):543-551.

In this episode of Better Edge, Sean W. P. Koppe, MD, moderates a panel of hepatologist, featuring Laura M. Kulik, MD, Andres Duarte, MD, Sarang B. Thaker, MD and Amanda C. Cheung, MD, as they discuss recent advances and challenges in liver research. The conversation addresses such key issues as the timing of immunotherapy in relation to transplants, the role of albumin management and the implications of these factors on patient outcomes. This discussion offers valuable insights to fellow researchers and clinicians navigating the complexities of liver medicine.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, highlight 4 key abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. Key Episode Timestamps 00:00:01 Introduction 00:00:45 Efimosfermin Alfa in MASH 00:05:56 PEth Testing 00:13:19 RETRACT-B 00:20:44 Linerixibat in PBC Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, continue their discussion on notable abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. If you haven't already, be sure to check out part 1 here! Key Episode Timestamps 0:00:00 LITMUS Study 0:05:47 Norursodeoxycholic Acid in PSC 0:10:12 GLOBE Score for PBC 0:15:11 Conclusion Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, is a chronic liver condition that affects nearly 1 in 3 people worldwide. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Unchecked, it can progress to a more severe form of disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH). Prognosticating the risk of disease progression in MASLD and MASH has traditionally involved liver biopsy, a process that involves removing a tissue sample with a hollow needle and then examining the sample under a microscope to diagnose and stage disease. However, biopsy has many limitations. Additionally, drug development for MASLD and MASH has proceeded slowly in part due to a reliance on liver biopsy to determine drug efficacy.Recently, increasing evidence is suggesting that non-invasive options, for example, imaging examinations along with blood tests that assess likelihood of disease progression such as the Enhanced Liver Fibrosis (ELF) Test, may effectively reduce the need for the more invasive alternative. Key experts in MASLD and MASH share their perspectives about how clinical evidence supports a shift in the way patients with MASLD and MASH could be evaluated in clinical practice and in research.Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Prof. William Rosenberg, Deputy Director of the Institute for Liver and Digestive Health at University College London as well as Dr. Veronica Miller, Director of the Forum for Collaborative Research at the University of California, Berkeley School of Public Health; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Associate Professor in the Section of Gastroenterology and Hepatology at Boston University.What you'll learn in this episode:Liver biopsy creates several obstacles for patients and has limitationsDrug development faces challenges by the reliance on biopsy as a measure of treatment effectivenessNon-invasive tools may be suitable alternatives to liver biopsy both in clinical practice and in drug developmentConnect with Matt GeeLinkedIn Connect with Veronica MillerLinkedInConnect with William RosenbergLinkedInConnect with Michelle LongLinkedInConnect with Arun SanyalVCU.edu Hosted on Acast. See acast.com/privacy for more information.

Hepatitis is inflammation of the liver and can be caused by a range of factors, such as viral infections, toxins, or some medical conditions. In 2018, Arkansas experienced a hepatitis A outbreak in which public health officials saw cases jump from just a handful to dozens each month. That outbreak subsided by the end of 2021, but hepatitis A isn't the only form of hepatitis affecting Arkansans. To learn more, we're joined on this episode of the Wonks at Work podcast by Dr. Matt Deneke, assistant professor in the Division of Gastroenterology and Hepatology at the University of Arkansas for Medical Sciences.

Host Roz is joined by new co-host Alberto Sanchez-Fueyo, MD, PhD to discuss the key articles of the June issue of the American Journal of Transplantation. Dr. Sanchez-Fueyo is a Professor of Hepatology, and the Academic Director of the Institute of Liver Studies, King's College, London. [02:51] Recipient toll-like receptor 4 determines the outcome of ischemia-reperfusion injury in steatotic liver transplantation in mice [10:47] Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study [21:35] Balancing equity and human leukocyte antigen matching in deceased-donor kidney allocation with eplet mismatch Editorial: Equitable allocation through human leukocyte antigen eplet matching: A promising strategy with several challenges [32:51] Impact of the lung allocation system score modification by blood type on US lung transplant candidates Editorial: From flawed to fairer: Reducing blood type bias in lung transplant allocation Recommended article: The economic value of a transplant nephrologist: The case for improving compensation models

Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics. In this episode, recorded live at the European Association for the Study of the Liver Congress (EASL) in Amsterdam, Tom shares invaluable insights into the evolving landscape of hepatology clinical trials and the unique challenges and opportunities shaping the field today. Listen now to stay ahead in the dynamic world of clinical trials.

Join Salinas Valley Health interventional radiologist, Juan Rodriguez, MD, as he explores the science and promise of Y-90 radioembolization, a groundbreaking treatment reshaping the fight against liver cancer. Learn how this targeted therapy works, what the procedure entails, and its impact on managing this complex disease.

In episode two of our Out of Programme (OOP) mini-series, we speak to Dr Wenhao Li, an ST6 Hepatology ACL at the Royal London Hospital. Wenhao shares his unforgettable OOP experience - spending a mont in the US on a BSG funded travelling fellowship. He takes us through his time in San Diego at the AASLD Liver Meeting, and the MASLD Research Centre. He also shared insights in to attending the EASL masterclass in Savannah. Keep an eye on your inbox for the weekly BSG newsletter, and get yourself to San Diego! Links: - https://www.bsg.org.uk/news/bsg-san-diego-travelling-fellowship-report Enjoying the podcast? Leave us a review on Apple (apple.co/3vCPuaz) or Spotify (spoti.fi/48y8oho). Get in touch with us at @BSGTrainees on Twitter.

The use of anti-diabetic medications such as pioglitazone or GLP-1 receptor agonists in the management of metabolic dysfunction-associated steatotic liver disease (MASLD) is discussed in this podcast. Dr Oliver Tavabie, Deputy Editor at FG and Hepatology Consultant at the Leeds Liver Unit, interviews Drs Scott Isaacs and Paul Brennan. Dr Scott Isaacs is the President of the American Association of Clinical Endocrinology and an Adjunct Associate Professor at Emory University School of Medicine, US. Dr Paul Brennan is a Senior Registrar and Honorary Research Fellow in Hepatology based at Ninewells Hospital, UK. They are authors of the paper "Role of anti-diabetic medications in the management of MASLD”, published online in Frontline Gastroenterology in February 2025. We hope you enjoy the #FGPodcast. Please follow @‌FrontGastro_BMJ. Listen to our regular podcasts and subscribe in Apple Podcasts and Spotify. If you enjoy our podcast, please rate us on your chosen platform, and leave us a review on the Frontline Gastroenterology Podcast page on Apple Podcasts: https://podcasts.apple.com/gb/podcast/fg-podcast/id942944229

Episode 33 - Christy Figueredo - Navigating GLP-1 Use in Pediatrics In this episode of Nutrition Pearls: the Podcast, co-hosts Bailey Koch & Megan Murphy speak with Christy Figueredo on the RD's role in patients on GLP-1 agonists. She is a member of the CPNP GLP-1 task force and shares her knowledge on managing pediatric patients on GLP-1 medications from her own clinical practice and the information gathered from the task force. Christy is a board-certified specialist in pediatric nutrition. She currently serves as the Dietitian for the department of Pediatric Gastroenterology, Hepatology and Nutrition at the University of Miami where she manages the unique nutritional needs of complex patients from infancy to adolescents in the outpatient setting.  She is an invited textbook chapter author for Infant and Pediatric Feeding and speaker on an array of childhood nutrition topics from the local to national level. She is a staunch child health advocate. Appointed to both the Miami-Dade WIC and Public-School Wellness Advisory committees collaborating with local stakeholders in childhood health and nutrition to provide a more equitable built environment for all. Nutrition Pearls is supported by an educational grant from Mead Johnson Nutrition.Resources:The SCOFF Questionnaire Binge Eating Disorder QuestionnaireAlliance for Eating Disorders - a great place for families or providers to start their search if they are unfamiliar with providers and support in their area.Food insecurity questionnaire Wadden TA, Chao AM, Moore MB, et al. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Current Obesity Reports. 2023;12(4). doi:https://doi.org/10.1007/s13679-023-00534-zMechanick JI, Apovian C, Brethauer S, et al. CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES – 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS. Endocrine Practice. 2019;25(12). doi:https://doi.org/10.4158/gl-2019-0406Almandoz JP, Wadden TA, Tewksbury C, et al. Nutritional considerations with antiobesity medications. Obesity. Published online June 10, 2024. doi:https://doi.org/10.1002/oby.24067‌Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2021;134(1):14-19. doi:https://doi.org/10.1080/00325481.2021.2002616Produced by: Corey IrwinNASPGHAN - Council for Pediatric Nutrition Professionalscpnp@naspghan.org

You can text us here with any comments, questions, or thoughts!In this episode, Kemi welcomes Dr. Allison Wu. Dr. Wu is Principal Investigator of the Wunderfull Lab. She is a clinician-researcher board certified in pediatric gastroenterology and nutrition as well as obesity medicine. Her research focuses on epidemiology and health services research in pediatric nutrition and obesity. She completed her fellowship in Pediatric Gastroenterology, Hepatology & Nutrition at Boston Children's Hospital and the Harvard-wide Pediatric Health Services Research Fellowship at Mass General Hospital for Children. She is also an alumnus of our Get That Grant® coaching program! Together, they explore Dr. Wu's unique journey that intertwines her love for science, nutrition, and working with children, shaped by her family's background in academia and the restaurant business. Join the conversation as Dr. Wu shares her experiences with coaching, her insights on how supportive environments can foster growth, confidence, and collaboration and the importance of grant writing in creating meaningful change. Conversation Highlights: Navigating maternity leave and career transitions The role of coaching in professional growth Building community and collaboration in academia The importance of intentionality in career development  Loved this convo? Please go find Dr. Wu on LinkedIn to show her some love!  

On this week's show, your host, Justin Mog, scrubs your aural environment of all toxins with two colleagues from the University of Louisville's Center for Integrative Environmental Health Science (CIEHS): Cat Aiton, MSW, is the Community Resource Coordinator for the Community Engagement Core of CIEHS, and Sarah Jump is the Communications & Marketing Specialist. Learn more about the Center at https://louisville.edu/ciehs On the show, we discuss what environmental health is and how we all play a role in either advancing it or detracting from it. We share some practical tips for keeping yourself, your family, and your entire community healthy in the face of a world of dangerous toxins and pollutants. We talk about how the Center is working to reach young people with empowering messages and walking the talk with more sustainable give-aways. You'll also learn about an upcoming Conference for Advancing Participatory Sciences and the importance of Report Back strategies for sharing findings with communities in a language that is meaningful to them. We'll also tell you all about the upcoming Environmental Health Youth Academy that the Center is organizing this summer (https://events.louisville.edu/event/2025-ciehs-cec-environmental-health-summer-youth-academy). The deadline to apply for this free summer series in June 16th and it is open to all high school sophomores, juniors, and seniors. CIEHS will host a two-week Youth Academy focused on environmental health in Louisville, July 14-24! At the end of the academy, participants will receive a certificate and a letter of completion (plus some free sustainable swag), making this a valuable addition to college or job applications. We have limited spots available—only 20 students will be accepted for this exclusive summer program, where you will learn directly from environmental health experts. Applications must be submitted by June 16th! Learn more and apply at https://louisville.edu/ciehs. The schedule for the Youth Academy is as follows: July 14 (In Person with lunch): Introduction to Environmental Health Banrida Wahlang, PhD, UofL Gastroenterology, Hepatology and Nutrition Lu Cai, MD, PhD, UofL Pediatrics, Radiation Oncology, and Pharmacology & Toxicology July 15 (Virtual): Air Quality and Health Petra Haberzettl, PhD, UofL Medicine, Diabetes & Obesity Center July 16 (Virtual): Water & Health Mayukh Banerjee, PhD, UofL Pharmacology & Toxicology July 17 (In Person with lunch): Community-Led Science Ted Smith, PhD, UofL Medicine and Pharmacology/Toxicology Rachel Neal, PhD, UofL Biology Luz Huntington-Moskos, PhD, RN, CPN, FAAN, UofL School of Nursing July 21 (Virtual): Energy & Health Sumedha Rao, Mayor's Office of Sustainability July 22 (Virtual): Mapping the Issues Charlie Zhang, PhD, UofL Geographic & Environmental Sciences, DJ Biddle, Director and Senior Lecturer, UofL Center for Geographic Information System Laura Krauser, UofL's Geographic Information Sciences Research Coordinator July 23 (Virtual): Communicating Sustainability Brent Fryrear, UofL Sustainability Council July 24 (In Person with lunch): Policy Advocacy and Storytelling Dr. Tony Arnold, UofL Law, Urban and Public Affairs, Resilience Justice Project Angela Story, PhD, UofL Anthropology and Director of Anne Braden Institute As always, our feature is followed by your community action calendar for the week, so get your calendars out and get ready to take action for sustainability NOW! Sustainability Now! is hosted by Dr. Justin Mog and airs on Forward Radio, 106.5fm, WFMP-LP Louisville, every Monday at 6pm and repeats Tuesdays at 12am and 10am. Find us at http://forwardradio.org The music in this podcast is courtesy of the local band Appalatin and is used by permission. Explore their delightful music at http://appalatin.com

The June 2025 podcast explores Patient education related to Nutrition Support and interviews Dr. Gail Cresci, Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University, and Staff in the Departments of Gastroenterology, Hepatology and Nutrition and Inflammation & Immunity at the Cleveland Clinic in Cleveland, OH. Dr. Cresci discusses the components of enteral nutrition and how these ingredients impact the gut microbiome. She presents the findings of her paper titled, “Understanding How Foods and Enteral Feedings Influence the Gut Microbiome” which reviews over 10,000 papers including both in vitro and in vivo studies to provide a great overview of the field. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US June 2025

A reversible liver condition is the fastest growing cause of liver transplantation in Western countries: Metabolic dysfunction-associated steatotic liver disease—or MASLD—affects patients worldwide. It's characterized by excessive fat accumulation in the liver and can progress into more severe forms of liver disease, potentially resulting in fibrosis, cirrhosis and liver failure.Risk factors for developing liver disease include obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Genetics, unhealthy dietary habits, and a sedentary lifestyle can also play significant roles in its development. Diagnosis typically involves imaging examinations along with blood tests that assess liver function and rule out other causes of liver disease.Disease management focuses on lifestyle modifications such as diet and exercise, though new medications are now being prescribed to slow and potentially reverse this condition. Regular monitoring of disease progression is also crucial for successful treatment.In this episode, experts in the field of liver disease address the progress happening in the recognition, diagnosis and treatment of the disease. Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Director of Clinical Research for the Section of Gastroenterology and Hepatology at Boston University; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Michael Betel, President and Founder of the Fatty Liver Alliance.What you'll learn in this episode:One of the biggest obstacles to diagnosing MASLD before it progresses stems from the lack of visibility and awareness of the diseaseMASLD is a reversible disease when caught in timeMASLD is more complex than a patient's diet or lifestyle—metabolic dysfunction plays a role Non-invasive testing has become an important tool in advancing patient careConnect with Matt GeeLinkedIn Connect with Michelle LongLinkedInConnect with Arun SanyalVCU.eduConnect with Michael BetelLinkedIn Hosted on Acast. See acast.com/privacy for more information.

Listen in as Paula Henao, MD; Rohit Loomba, MD, MHSc; Cheryl Pirozzi, MD, MS; and Corinne Young, NP, FCCP, discuss their screening and monitoring strategies for patients with alpha-1 antitrypsin deficiency, including:Why early detection is key for improving patient outcomesHow to monitor through use of noninvasive imaging and biopsy per guideline recommendationsHow to coordinate patient care to provide much-needed multidisciplinary careWhat therapies in the pipeline could transform the treatment landscape for this genetic disease PresentersPaula Henao, MDAssistant Professor of MedicineDivision of Pulmonary, Allergy and Critical Care MedicinePenn State Hershey Medical CenterHershey, PennsylvaniaRohit Loomba, MD, MHScProfessor of MedicineChief, Division of Gastroenterology and HepatologyDirector, MASLD Research CenterUniversity of California, San DiegoSan Diego, CaliforniaCheryl Pirozzi, MD, MSAssociate Professor of Internal MedicineDivision of Pulmonary and Critical Care MedicineUniversity of UtahSalt Lake City, UtahCorinne Young, NP, FCCPPresident/FounderAssociation of Pulmonary Advanced Practice ProvidersColorado Springs, ColoradoLink to full program: https://bit.ly/4dgCRnq

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mark Benson, MD Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.

In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Cary Sauer about Competency-Based Medical Education (CBME) to break down this concept and all the related terminology that is part of this approach to medical training. If you're confused about CBME, EPAs, milestones and competencies, this episode is for you! Dr. Sauer is a Pediatric Gastroenterologist specializing in the care of children with IBD and Division Chief at Children's Healthcare of Atlanta and Emory University.Learning Objectives:Understand what Competency-Based Medical Education (CBME) means and how it differs from traditional time-based models of medical trainingUnderstand how milestones, competencies and EPAs relate to one another within the CBME frameworkRecognize the central role of entrustment and how that can is incorporated into workplace-based assessments of traineesLinks:Pediatric GI Milestones (v2.0)NASPGHAN EPA resourcesABP EPAs for subspecialtiesNorth American Society for Pediatric Gastroenterology,  Hepatology, and Nutrition Position Paper on Entrustable  Professional Activities: Development of Pediatric  Gastroenterology, Hepatology, and Nutrition Entrustable  Professional ActivitiesEducating pediatric gastroenterology fellows: milestones, EPAs, & their application within a new educational curriculumImplementing entrustable professional activities in pediatric fellowships: facilitating the processSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice. Intended for hepatologists, gastroenterologists, and other clinicians managing liver disease, Liver Lineup will unpack the latest research, debate emerging controversies, and spotlight developments that could shape — or sharpen — day-to-day practice, all with unfiltered perspective and clarity. Brown is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University Reau is a professor of internal medicine, the Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and the section chief of Hepatology at Rush University Medical Center. In the inaugural episode, Brown and Reau introduce the mission behind Liver Lineup and share why they created the podcast. Driven by a shared commitment to education, clinical excellence, and elevating the conversation around liver disease, the hosts describe their hope to offer practicing clinicians a clear, concise, and engaging way to keep up with the latest news and innovations in hepatology. They aim to highlight data that's not only new, but meaningful — spotlighting developments that can improve patient care today and shape best practices tomorrow. Together, the Brown and Reau set the stage for what's to come: expert commentary on major liver meetings including Digestive Disease Week, European Association for the Study of the Liver Congress, The Liver Meeting from the American Association for the Study of Liver Diseases, and the American College of Gastroenterology Annual Meeting; coverage of key topics like MASLD, liver cancer, viral hepatitis, and transplant; and conversations with colleagues across the hepatology spectrum. From debates over practice-changing data to discussions on care pathways and diagnostics, Liver Lineup aims to keep clinicians informed, engaged, and ready to translate insight into impact. Looking ahead, Brown and Reau preview upcoming episodes covering major hepatology updates from Digestive Disease Week 2025 and European Association for the Study of the Liver Congress 2025 — with more to follow throughout the year.

Host: Darryl S. Chutka, M.D. Guests: Cadman L. Leggett, M.D., and Chamil C. Codipilly, M.D. Occasional heartburn from gastroesophageal reflux is usually nothing more than an occasional nuisance for most patients.  However, when the reflux becomes chronic, it can become more serious.  One complication is Barrett's esophagus. On occasion, Barrett's can develop into esophageal adenocarcinoma, an aggressive malignancy with a survival rate of only around 20% at 5 years.  Although usually seen in those with chronic acid reflux, Barrett's can occasionally occur in those without any clinical evidence of acid reflux.  When should a patient with acid reflux receive an upper endoscopy?  What's the significance of finding Barrett's esophagus on an endoscopy?  How often does Barrett's develop into esophageal cancer and does treatment prevent this from happening?  In this podcast, these are just some of the questions I'll be asking our guests, Cadman L. Leggett, M.D., and Chamil C. Codipilly, M.D., both from the Division of Gastroenterology and Hepatology at the Mayo Clinic as we discuss Barrett's Esophagus. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Dr. Vivian Abenaa Asamoah discusses H. Pylori with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights       ________________________________________________________________________________________________________ Dr Vivian Abenaa Asamoah is a board-certified Gastroenterologist who combines conventional and Integrative Medicine.   She went to the University of Geneva Medical School and did a residency and fellowship in Gastroenterology, Hepatology and Nutrition at John's Hopkins.  You can find out more about her on the HoustonGastroInstitute.com Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

Send us a textThis week we bring back our friend and friend of the show, Dr. Ashish S. Patel! Dr. Patel takes us on a global journey through the evolving landscape of pediatric inflammatory bowel disease treatment, revealing contrasts between approaches across continents and highlighting gaps in how new medications reach children.While adult IBD patients have benefited from an explosion of treatment options over the last two decades, children remain limited primarily to anti-TNF biologics as their only FDA-approved options. This forces physicians to fight insurance battles for access to newer medications or enroll patients in clinical trials that come years too late. "We have to bring evaluation of these medications to pediatrics concurrently with adult populations," Dr. Patel explains, sharing how advocacy efforts aim to shift this paradigm.The conversation takes a fascinating turn when comparing treatment philosophies worldwide. At the World Congress in Buenos Aires, nutritional therapy, probiotics, and dietary interventions dominated discussions—a striking contrast to North American conferences featuring pharmaceutical companies. This reveals how resource availability shapes medical approaches, with Latin American physicians developing expertise in nutritional interventions while North American practices focus on biologics.Dr. Patel's most hopeful insights come from current research aiming to personalize treatment based on a patient's unique profile. Studies collecting genetic information, microbiome data, and environmental exposures may eventually allow doctors to determine the optimal intervention—whether medication, diet modification, or environmental change—for each child at diagnosis. "In the near future, at least for certain types of IBD, we're talking about something that's curative rather than just therapeutic," he shares, offering hope that we're moving beyond symptom management toward addressing root causes.Join us for this eye-opening conversation that challenges conventional thinking about how we research, develop, and implement treatments for one of medicine's most complex childhood conditions.Links: ImproveCareNowNorth American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN)Let's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

El doctor Huerta, nos cuenta sobre un estudio publicado en Clinical Gastroenterology and Hepatology, el cual identifica tres condiciones que aumentan significativamente el riesgo de daño hepático en personas que consumen alcohol.

Hepatitis means inflammation of the liver. The liver is a vital organ that processes nutrients, filters the blood, and fights infections. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common types of viral hepatitis are hepatitis A, hepatitis B, and hepatitis C. ​Hepatitis D, also known as “delta hepatitis,” is a liver infection caused by the hepatitis D virus (HDV). Hepatitis D only occurs in people who are also infected with the hepatitis B virus. Hepatitis D is spread when blood or other body fluids from a person infected with the virus enters the body of someone who is not infected. Hepatitis D can be an acute, short-term infection or become a long-term, chronic infection. Hepatitis D can cause severe symptoms and serious illness that can lead to life-long liver damage and even death. People can become infected with both hepatitis B and hepatitis D viruses at the same time (known as “coinfection”) or get hepatitis D after first being infected with the hepatitis B virus (known as “superinfection”). There is no vaccine to prevent hepatitis D. However, prevention of hepatitis B with hepatitis B vaccine also protects against future hepatitis D infection. ​Hepatitis E is a liver infection caused by the hepatitis E virus (HEV). HEV is found in the stool of an infected person. It is spread when someone unknowingly ingests the virus – even in microscopic amounts. In developing countries, people most often get hepatitis E from drinking water contaminated by feces from people who are infected with the virus. In the United States and other developed countries where hepatitis E is not common, people have gotten sick with hepatitis E after eating raw or undercooked pork, venison, wild boar meat, or shellfish. In the past, most cases in developed countries involved people who have recently traveled to countries where hepatitis E is common. Symptoms of hepatitis E can include fatigue, poor appetite, stomach pain, nausea, and jaundice. However, many people with hepatitis E, especially young children, have no symptoms. Except for the rare occurrence of chronic hepatitis E in people with compromised immune systems, most people recover fully from the disease without any complications. No vaccine for hepatitis E is currently available in the United States. (credits CDC)

Many people confuse fatty liver disease with cirrhosis. In this podcast, Salinas Valley Health gastroenterologist Vikram Patel, MD, clarifies the distinctions between the two, revealing why early intervention in fatty liver disease is vital to avoid the irreversible consequences of cirrhosis.

April 19 is World Liver Day, a day to raise awareness about the health of our often-overlooked yet vital liver. Liver diseases are a leading cause of mortality in the Philippines, accounting for 27.3 per 1,000 deaths, according to a 2023 study published in the Annals of Hepatology.Experts also warn that 10-20% of Filipinos may have non-alcoholic fatty liver disease, which can lead to serious complications if left untreated.To share tips on how to take care of our liver, we spoke with Dr. Maria Vanessa H. De Villa, the first surgeon in the country to perform a pediatric liver transplant and the director of The Medical City's Center for Liver Disease Management and Transplantation.Interview by Edg Adrian EvaAudio editing by Jayson Mariñas

On this Line One, join Dr. Justin Clark for a discussion about all things liver.

In this episode, hosts Drs. Peter Lu and Temara Hajjat talk to Dr. Jean Molleston about drug-induced liver injury (DILI) in children.  Dr. Molleston is the former Division Chief of Gastroenterology, Hepatology, and Nutrition at Riley Children's and Professor of Clinical Pediatrics at University of Indiana School of Medicine.Learning Objectives:Understand the definition of DILI and signs that should raise our concern for this diagnosis.Recognize common causes of DILI, including both medications and supplements.Recognize the signs of drug reaction with eosinophilia and systemic symptoms or DRESS syndrome.Links:LiverTox: Searchable resource on drug-induced liver injurySupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

00:00:00 - Surf's Up: Season 6 Episode 2Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on disease epidemiology and what it can teach us about the relative importance of alcohol and diet on disease progression. Our newsmaker, hepatology KOL and frequent Surfer Hannes Hagstrom, discusses what a recent paper demonstrates about the impact of MASLD on 15-year mortality and cause of death and how this information can improve patient care. Finally, our Expert, Shelbyville, Indiana internist Emily Ann Andeya, discusses her path from practicing internal medicine to focus on liver health (HINT: the common theme is insulin resistance).00:04:40 - IntroductionHost Roger Green briefly describes this episode's three sections and one key lesson from each.00:05:49 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 2 The second portion of our Roundtable focuses on relative impact of alcohol and diet on disease progression and overall mortality and morbidity. It starts with Aleksander Krag sharing the highlights of his epidemiology presentation at the Emerging Trends Conference. Dr. Krag points out that while the vast majority of SLD patient live with MASLD, the vast majority of hospitalized patients and those living with late-stage cirrhosis live with ALD. Similarly, for the average patient, living with MetALD is more lethal than living with MASLD. Aleksander points out another challenge in defining where a patient lives on the ALD -> MetALD -> MASLD spectrum: patients' level of alcohol consumption is likely to change over time and many ALD or MetALD cirrhosis patients stop drinking altogether. The rest of this section considers the importance of stigma in correctly classifying patients and why genetics may become key to a message that minimizes patient stigma.00:25:50 - Newsmaker: Hepatology Researcher and KOL Hannes Hagstrom of the Karolinska Institute joins Roger to discuss cause-specific mortality in Swedish MASLD patientsOn March 24, the Journal of Hepatology posted a paper titled Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. Co-author Hannes Hagstrom joins Roger to discuss the paper's key findings and implications for care. The key finding: living with MASLD leads to a significant increase in 15-year mortality. The most frequent cause of death among MASLD patients is cardiovascular disease, but the greatest increases in relative risk were due to HCC (HR ~ 35) and extra-hepatic cancers (HR ~ 26). Hannes points out that these results can serve as the beginning of a process where physicians can compute the risk at which individual patients place themselves through diet or alcohol patterns, which can aid patient understanding of the disease.00:44:22 - Experts: Internist Emily Ann Andeya discusses how she developed the commitment to treating liver disease that made her a "unicorn" in the words of one AASLD panelist and also brought her to attend the Emerging Trends Conference last monthRoger first met Emily Ann Andeya when she asked a question at a session of last fall's The Liver Meeting, and again at the Emerging Trends Conference, where Emily and her colleagues were likely the only primary care physicians in the room. Emily describes the path by which she went from wanting to be a cardiologist during medical school in the Philippines through years of nursing in the US to primary care practice and, how, focus on the liver as a key to overall metabolic health. Listen as Emily explains the importance of understanding insulin resistance in her transition, and how her vision affects the way she and her colleagues practice, the goals they set, and the exceptional levels of care they achieve.01:08:56 Business Report

durée : 00:05:26 - Avec sciences - par : Alexandre Morales - Dans The Lancet Gastroenterology & Hepatology, une équipe internationale de scientifiques présente un nouveau test rapide, peu cher, facile à réaliser.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

The gut microbiome has become one of my favorite topics, especially since, like many of my fellow scleroderma warriors, I experience stomach issues. Today, we dive deep into the intestinal challenges that come with our diagnosis with Dr. Joy Liu. She provides an in-depth and insightful discussion, breaking down these complex issues with great clarity.

If mealtimes feel like a battle in your home, you're not alone. Many parents struggle with picky eating, and I've experienced it firsthand with my daughter — who, like many kids, has earned the label of a "picky eater" in our family. But how do you know when picky eating is more than just a phase? I recently heard about Pediatric Feeding Disorders (PFDs) and was shocked, confused, and intrigued by the topic. When I learned how PFDs affect millions of children, yet they often go undiagnosed or misunderstood, leaving parents feeling frustrated and helpless, I knew that I had to learn more and spread the word. That's why in this episode of Chick Chat, we sit down with Jaclyn Pederson, CEO of Feeding Matters, to break it all down for us. Who is Jaclyn Pederson? With over a decade of experience in program development, Jaclyn Pederson's broad knowledge of programming in the public and social sectors includes program and strategic initiative design, fund development, special events, grant writing, and community engagement. A system thinker and positive team builder, she uses transformational leadership principles to develop energized and efficient workgroups that influence significant organizational and systemic change for all affected by pediatric feeding disorder – such as the development of the expanded PFD Alliance. Jaclyn also manages Feeding Matters' strategic partnerships with numerous professional associations including American Speech-Language-Hearing Association (ASHA), American Society of Parenteral and Enteral Nutrition, and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). What Did We Discuss? In this episode, Jaclyn and I discussed everything about pediatric feeding disorders — from signs and symptoms to navigating and overcoming PFDs. Jaclyn also shares her expertise on when to seek help, how feeding disorders can impact a child's development, and what treatment options are available. Here are several of the questions that we covered in our conversation: What are Pediatric Feeding Disorders (PFDs)?  Can you tell us a bit about your personal experience with PFDs?  How common are PFDs?  What should families know about PFDs?  What are the signs and symptoms of PFDs that parents should be aware of?  What myths or misconceptions do you often encounter about picky eaters versus feeding disorders? How can a parent know when it's time to get their child evaluated for “picky eating”? Is there a connection between feeding disorders and developmental delays? How can parents advocate for their children when seeking help for feeding challenges? What does treatment for a PFD look like?  What advice do you have for parents feeling overwhelmed by their child's feeding challenges and looking for support? If you think your child's mealtime struggles go beyond picky eating, this episode is a must-listen. Jaclyn shares expert insights to help parents feel more confident in identifying and addressing Pediatric Feeding Disorders. Listen now, and don't forget to share this episode with a fellow parent who may need this information! Jaclyn's Resources Website: FeedingMatters.org Instagram: @feedingmatters Facebook: @feedingmatters Mentioned in the episode: Family Guide to Pediatric Feeding Disorder Thank you for listening to our podcast. Cheers to finding the best way to nourish your children! Learn more about your ad choices. Visit megaphone.fm/adchoices

This podcast features Kerstin (Keri) Austin, MD, Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine in Madison, WI. Dr. Austin became interested in nutrition during her residency and quickly realized that there wasn't much nutrition in the curriculum. As a Fellow, she connected with Dr. Jayshil (Jay) Patel through ASPEN and was encouraged by him to apply for the Nestlé Nutrition Fellowship. This was her first exposure to dedicated nutrition training. She emphasizes the importance of nutrition as it affects every discipline in every area of medicine. A member of the Physician Engagement Committee, Dr. Austin shares how her involvement with ASPEN has opened up career opportunities. She stresses the importance of mentorship and peer support in nutrition, urging clinicians interested in nutrition to actively participate in the community to advance their careers. Physician Spotlight is a forum for outstanding Senior Leaders, Young Rising Stars, and International Colleagues in the field of nutrition to discuss important topics and ideas that impact patient care. Visit the ASPEN Physician Community at www.nutritioncare.org/physicians

Early detection is critical for improving cancer survival rates, yet pancreatic cancer remains challenging to detect. A recent breakthrough from Mayo Clinic researchers offers new hope. Artificial intelligence models demonstrate the potential to detect pancreatic cancer earlier and with remarkable accuracy. Learn more about this life-changing innovation in early cancer detection. Featured experts include Ajit Goenka, M.D., radiologist and professor of radiology at Mayo Clinic's Comprehensive Cancer Center and Suresh Chari, M.D., professor, Department of Gastroenterology, Hepatology, and Nutrition in the Division of Internal Medicine at MD Anderson Cancer Center.Get the latest health information from Mayo Clinic's experts, subscribe to Mayo Clinic's newsletter for free today:  https://mayocl.in/3EcNPNc

Low FODMAP and Low Carb Diets Outperform Drugs for IBS Treatment: In this episode of Intelligent Medicine, Nutritionist Leyla Muedin discusses a study published in the Lancet Gastroenterology and Hepatology Journal examining the effectiveness of diet versus drug interventions in managing irritable bowel syndrome (IBS). The study presents findings from a single-blind, randomized control trial comparing low FODMAP, low carbohydrate diets, and pharmacological treatments. Results indicate that both diet groups significantly outperformed drug treatments in symptom severity reduction, with specific benefits observed in patients suffering from constipation and diarrhea-dominant IBS. Leyla highlights the advantages of dietary interventions as first-line treatments for IBS, the practical aspects of implementing these diets, and the study's broader implications for improving quality of life for IBS sufferers.

Guest: Dr. Richard Noel, MDEarn 0.1 ASHA CEU for this episode with Speech Therapy PD: https://www.speechtherapypd.com/course?name=The-Medical-Domain-of-Pediatric-Feeding-DisorderIn this episode, Dr. Richard Noel joins the discussion to shed light on Pediatric Feeding Disorder (PFD) and its medical domain. Dr. Noel shares his journey to becoming a pediatric GI specialist and explores the critical components of managing PFD. Key topics include the importance of growth and nutrition, management of upper GI tract issues, and the significance of airway and lung concerns. Dr. Noel also addresses common misconceptions about reflux in infants and the use of various appetite stimulants such as ciproheptadine and mirtazapine. Viewers will gain valuable insights into constipation management, the role of scheduled toileting, and the importance of multidisciplinary care in treating PFD. The conversation underscores the need for better medical understanding and care strategies for children with PFD.Timeline:00:00 Introduction and Guest Welcome01:41 Journey to Becoming a Pediatric Gastroenterologist05:32 Understanding Pediatric Feeding Disorders06:51 Medical Domain of PFD: Key Considerations08:24 Addressing Nutritional Concerns14:17 Managing Constipation in PFD21:39 Behavioral Strategies for Feeding23:36 Family Involvement in Feeding Therapy26:04 Family Routines and Feeding Therapy26:47 Medications for Appetite Stimulation27:03 Ciproheptadine: Uses and Effects31:18 Mirtazapine: An Appetite Stimulant34:49 Megastrol: A Powerful Appetite Stimulant37:07 Managing GI Issues in Children38:03 Reflux and Vomiting in Infants43:09 Cyclical GI Disorders: Abdominal Migraines and More47:20 The Role of Multidisciplinary Teams in Pediatric Care48:56 Challenges in Pediatric Feeding Disorder Education53:46 Advocacy and Access to Multidisciplinary CareAbout the Guest: Dr. Richard Noel was born in Mexico City and grew up in San Antonio, TX. He has MD/PhD degrees from the University of Texas Southwestern Medical Center in Dallas and did a residency in Pediatrics at Wake Forest University in NC. He trained in Pediatric Gastroenterology at Cincinnati Children's Hospital Medical Center, where he developed an interest in working with children with pediatric feeding disorders. He worked for 10 years at the Children's Hospital of Wisconsin with Dr. Colin Rudolph and then transitioned to Duke University, where is currently Division Chief for Pediatric Gastroenterology, Hepatology, and Nutrition.Watch this Interview on YouTube: https://youtu.be/NVGPdIzfobs

Almost 2400 years ago, Hippocrates said "All disease begins in the gut"; and he was right. With modern scientific methods and studies to prove it, we can see exactly how and why all dieases begin in your gut, and what you can do to stop them. 93% od the leading causes of death are connected to your gut, and this episode is going to explain why that it, how it happens and to give you the tools you need to not only protect yourself and your loved ones, but even to reverse almost any diease.   TOPICS DISCUSSED: Reversing 93% of the leading causes of death The machanisms of how all diease begins in your gut How endotoxins (gut toxins) circulate around your body What they do to your organ systems and your body How to heal and seal your gut Reverse chronic inflammatory diseases How to heal from almost anything   Leave us a Review: https://www.reversablepod.com/review   Need help with your gut? Click the link, or visit gutsolution.ca for help: Get help now   Supplements: Get 15% off Practitioner Grade Supplements (forever) by creating an account   Contact us: reversablepod.com/tips    SOCIAL MEDIA: Instagram  Facebook  YouTube     STUDIES FOR REFERENCE: 1. LPS and Liver Disease: ·       Key Study: Lipopolysaccharides promote hepatic steatosis by activating the TLR4-NF-κB pathway in hepatocytes (Cai et al., 2012, Hepatology). Link: https://pubmed.ncbi.nlm.nih.gov/22025365/ 2. LPS and Kidney Disease: ·       Key Study: Role of lipopolysaccharide in the pathogenesis of kidney injury in sepsis (Matsushita et al., 2021, Nephrology). Link: https://pubmed.ncbi.nlm.nih.gov/33460487/ 3. LPS and Diabetes: ·       Key Study: Gut-derived endotoxin and metabolic inflammation in type 2 diabetes (Cani et al., 2007, Diabetologia). Link: https://pubmed.ncbi.nlm.nih.gov/17471239/ 4. LPS and Cancer: ·       Key Study: Gut microbiota-mediated inflammation in obesity: A link with gastrointestinal cancer (Cani et al., 2018, Nature Reviews Gastroenterology & Hepatology). Link: https://pubmed.ncbi.nlm.nih.gov/29348450/ 5. LPS and Cerebrovascular Disease: ·       Key Study: LPS-induced systemic inflammation exacerbates brain damage in ischemic stroke (Chen et al., 2016, Stroke). Link: https://pubmed.ncbi.nlm.nih.gov/26846899/ 6. LPS and Parkinson's Disease: ·       Key Study: Lipopolysaccharide induces neuroinflammation and dopaminergic neuron loss in Parkinson's disease models (Qin et al., 2007, Journal of Neuroscience). Link: https://pubmed.ncbi.nlm.nih.gov/17360907/ 7. LPS and Hypertension: ·       Key Study: Role of gut-derived endotoxemia in systemic inflammation and hypertension (Tang et al., 2017, Hypertension). Link: https://pubmed.ncbi.nlm.nih.gov/28209750/ 8. LPS and Colon/Gut Diseases: ·       Key Study: Lipopolysaccharides promote intestinal inflammation by disrupting the epithelial barrier (Schmidt et al., 2015, Gut). Link: https://pubmed.ncbi.nlm.nih.gov/25691570/ 9. Studies Supporting LPS's Role in Alzheimer's: ·       Study 1: Microbiome-derived lipopolysaccharide enriched in the perinuclear region of Alzheimer's disease brain (Zhao et al., 2017, Frontiers in Immunology). Link: https://pubmed.ncbi.nlm.nih.gov/28928740/ ·       Study 2: Lipopolysaccharides cause neuronal death and cognitive decline (Molecules, 2022). Link: https://pubmed.ncbi.nlm.nih.gov/35011994/ ·       Study 3: Neuroinflammation and Alzheimer's disease: Mechanisms of action (Nature Neuroscience, 2019). Link: https://pubmed.ncbi.nlm.nih.gov/30842661/

Update your approach to cirrhosis evaluation and management with Dr. Scott Matherly Associate Professor of Hepatology and Gastroenterology at Virginia Commonwealth University  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro, disclaimer, guest bio Case from Kashlak; Definitions Cirrhosis Diagnosis and Initial Evaluation  Cirrhosis Physical Examination  Decompensated Cirrhosis Management  Ascites and TIPS MELD and transplant consideration Outro Credits Written and Produced by: Elena Gibson MD Infographic and Cover Art: Edison Jyang MD Hosts: Paul Williams MD, FACP; Elena Gibson MD     Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Scott Matherly MD  Sponsor: Rocket Money Cancel your unwanted subscriptions and reach your financial goals faster with Rocket Money. Go to RocketMoney.com/CURB today.  Sponsor: Rosetta Stone Visit rosettastone.com/curbsiders for 50% off unlimited access to 25 language courses for the rest of your life.  Sponsor: Grammarly  Download Grammarly for FREE at grammarly.com/PODCAST.

Earn 0.1 ASHA CEU for this episode with Speech Therapy PD: www.speechtherapypd.com/course?name=Feeding-Matters-Leading-the-Way-for-ARFID-and-PFDIn the first episode of 2025, Michelle is joined by Jaclyn Pederson, MHI, CEO of Feeding Matters, and William Sharp, PhD, Director of Children's Multidisciplinary Feeding Program (Atlanta, GA) and Professor at Emory University School of Medicine, to lay the foundation for a year of combining passion, advocacy, and learning. These guests share their expertise and highlights from a recent journal publication on how the diagnoses of “Pediatric Feeding Disorder” and “Avoidant Restrictive Feeding Intake Disorder” are individualistic while simultaneously overlapping to capture the unique needs of the little ones on our caseloads. Additionally, they share practical insight into the roles and responsibilities of various team members, such as the SLP and the psychologist, in evaluating and treating these little ones as part of an interprofessional practice team.About the Guests: Jaclyn Peterson, MHI: With more than a decade of experience in program development, Jaclyn Pederson's broad knowledge of programming in the public and social sectors includes program and strategic initiative design, fund development, special events, grant writing, and community engagement. A system thinker and positive team builder, she uses transformational leadership principles to develop energized and efficient workgroups that influence significant organizational and systemic change for all affected by pediatric feeding disorder –such as the development of the expanded PFD Alliance. Jaclyn also manages Feeding Matters' strategic partnerships with numerous professional associations, including the American Speech-Language-Hearing Association (ASHA), the American Society of Parenteral and Enteral Nutrition, and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).William Sharp, PhD is a clinical psychologist and professor in the department of pediatrics at Emory University School of Medicine. He is also the Director of Children's Healthcare of Atlanta's Multidisciplinary Feeding Program. In this role, Dr. Sharp leads a team of professionals that includes psychologists, physicians, speech-language pathologists, and dietitians who evaluate and treat children with pediatric feeding disorder and avoidant restrictive food intake disorder (ARFID). His research interest focuses on identifying the cause, consequences, and treatment of chronic food refusal in pediatric populations. His most recent work involves developing and evaluating a training curriculum for therapists to deliver a manual-based intervention for food selectivity - or extremely narrow dietary in children with ARFID.Hosted by: Michelle Dawson MS, CCC-SLP, CLC, BCS-SWatch the full video interview on YouTube: https://www.youtube.com/@speechtherapypd